Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients
Active, not recruiting · Phase 2 · NCT03916627
Conditions: Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma
At a glance
- Research payments reported, 2025
- $1.4M
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 65
About the trial
- Sponsor
- Regeneron Pharmaceuticals
- Tested
- cemiplimab (drug), Platinum Doublet (drug), fianlimab (drug)
- Dates
- Started 2019-07-23; completion 2030-05-14
- Results posted
- Not yet
This study is being done to better understand whether or not cemiplimab by itself and in combination with other treatments given prior to surgery will cause your tumor to respond in a beneficial way; whether the drug(s) are safe and what side effects they cause; and other details about how they function in the body. One of the treatments that will be combined cemiplimab is another experimental drug called fianlimab. In this form, cemiplimab and fianlimab will each individually be called "study drug" or "study drugs" when combined. Cemiplimab (also known as REGN2810) and fianlimab (also known as REGN3767) are both a type of drug called a monoclonal antibody. Antibodies are proteins natural…
From ClinicalTrials.gov, last updated 2026-04-06. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $1.4M in research payments for this study in 2025 (12 payments).
Products named: Libtayo
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Icahn School of Medicine at Mount Sinai $1.4M
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.